ASH 2021 | Acalabrutinib window prior to frontline therapy in aggressive B-cell lymphoma
Mark Roschewski
• 14 Dec 2021
Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, reports the preliminary results, including dynamic changes in circulating tumor DNA (ctDNA) from the Phase II study (NCT04002947) of acalabrutinib window prior to frontline therapy in untreated aggressive B-cell lymphoma. Acalabrutinib before frontline therapy showed activity in various subtypes of B-cell lymphoma. Additionally, early changes in ctDNA were tightly correlated with changes on CT scans and may predict response to targeted agents as early as one week. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
